About Jiangsu Aidea Pharmaceutical Company

The company was founded in 2009 and listed on the Shanghai Stock Exchange Science and Technology Innovation Board in 2020. The company is committed to building a complete R&D pipeline for new HIV antiviral drugs, and has core technical advantages and product first-mover advantages in this field. It strives to provide patients with more comprehensive and diverse drug choices, continuously meet the urgent needs of domestic AIDS treatment upgrades, and strive to become a leader in the field of AIDS treatment. The company's main business focuses on anti-HIV and human protein fields. The company's pharmaceutical preparations mainly include enovirin tablets, enomide tablets, injectable urokinase, senna granules, etc. Corporate honors: It won the title of “2019-2020 Yangzhou Civilized Unit”, the crude product of human urinary kinin peptide enzyme was certified as a high-tech product in Jiangsu Province in 2014, and the first-class anti-AIDS drug ACC007 was included in the “Major New Drug Creation” science and technology project of the 13th Five-Year Plan.